ReviewWorld journal of gastroenterology2023
Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.
Review in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Correlation between sarcopenia and cirrhosis: a meta-analysis.Frontiers in nutrition · 2023Pooled it
- Identification of PTPRR gene associated with cirrhosis and sarcopenia based on bioinformatics and machine learning.European journal of clinical nutrition · 2026Article
- Evaluation of Kidney Function in Cirrhosis: Methods and Pitfalls.Diagnostics (Basel, Switzerland) · 2026Review
- Functional metagenomic reconstruction of microbial pathways altered by probiotic supplementation in liver failure.Frontiers in cellular and infection microbiology · 2026Article
- A Review of Recent Advances in Fecal Microbiota Transplantation for the Treatment of Hepatic Encephalopathy.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Rifaximin and sarcopenia in cirrhosis: Commentary on a promising but complex relationship.World journal of hepatology · 2025Article
- Machine learning to identify potential biomarkers for sarcopenia in liver cirrhosis.World journal of hepatology · 2025Article
- Gut microbiota analysis in cirrhosis and non-cirrhotic portal hypertension suggests that portal hypertension can be main factor of cirrhosis-specific dysbiosis.Scientific reports · 2025Article
- Inflammatory sarcopenia, a novel concept in chronic liver disease: insights from magnetic resonance imaging biomarkers.Translational gastroenterology and hepatology · 2025Article
- Correlation study on gut microbiota and myosteatosis in patients with liver cirrhosis.Frontiers in nutrition · 2025Article
- Impact of low preoperative appendicular skeletal muscle mass on postoperative complications and short-term outcomes in liver transplant recipients: a propensity score-matched retrospective study.Frontiers in surgery · 2025Article
- Joint effects of prognostic nutritional index and skeletal muscle index on prognosis of decompensated cirrhosis: a retrospective cohort study.Therapeutic advances in chronic disease · 2025Article
- Exploring the Relationship Between Gut Microbiota and Sarcopenia Based on Gut-Muscle Axis.Food science & nutrition · 2024Review
- Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies.Archives of pharmacal research · 2024Review
- Efficacy and Safety of a Probiotic ContainingJournal of clinical medicine · 2024Article
- Body Composition in Chronic Liver Disease.International journal of molecular sciences · 2024Review
- Article
- Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decreased muscle mass and function, also known as sarcopenia, is common in patients with cirrhosis and is associated with a poor prognosis. Although the pathogenesis of this disorder has not been fully elucidated, a disordered gut-muscle axis probably plays an important role. Decreased barrier function of the gut and liver, gut dysbiosis, and small intestinal bacterial overgrowth (SIBO) can lead to increased blood levels of ammonia, lipopolysaccharides, pro-inflammatory mediators, and myostatin. These factors have complex negative effects on muscle mass and function. Drug interventions that target the gut microbiota (long-term use of rifaximin, lactulose, lactitol, or probiotics) positively affect most links of the compromised gut-muscle axis in patients with cirrhosis by decreasing the levels of hyperammonemia, bacterial translocation, and systemic inflammation and correcting gut dysbiosis and SIBO. However, although these drugs are promising, they have not yet been investigated in randomized controlled trials specifically for the treatment and prevention of sarcopenia in patients with cirrhosis. No data exist on the effects of fecal transplantation on most links of gut-muscle axis in cirrhosis; however, the results of animal experimental studies are promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.